Press Releases Year None20192018201720162015201420132012 August 20, 2019 Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019 August 13, 2019 Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program August 12, 2019 Lineage Cell Therapeutics Launches New Corporate Brand August 8, 2019 BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update August 1, 2019 BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019 July 31, 2019 BioTime Announces Name Change to Lineage Cell Therapeutics July 11, 2019 BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System July 2, 2019 BioTime Conducts Sale of Shares in OncoCyte Corporation May 22, 2019 BioTime Announces Appointment of General Counsel May 10, 2019 BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen® May 9, 2019 BioTime Reports First Quarter 2019 Financial Results and Provides Business Update May 6, 2019 BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury May 3, 2019 BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 May 2, 2019 BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting April 26, 2019 BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference April 16, 2019 BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) March 18, 2019 BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019 March 14, 2019 BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update March 11, 2019 BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company March 7, 2019 BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019 March 4, 2019 BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 February 26, 2019 BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019) February 14, 2019 BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias January 30, 2019 BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer January 7, 2019 BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD January 4, 2019 BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase January 2, 2019 BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
August 20, 2019 Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019
August 13, 2019 Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program
August 1, 2019 BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
July 11, 2019 BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
May 10, 2019 BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
May 6, 2019 BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
May 3, 2019 BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
May 2, 2019 BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
April 26, 2019 BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
April 16, 2019 BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
March 18, 2019 BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
March 14, 2019 BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 11, 2019 BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
March 7, 2019 BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
March 4, 2019 BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
February 26, 2019 BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
February 14, 2019 BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
January 30, 2019 BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
January 7, 2019 BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
January 4, 2019 BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
